Alzamend Neuro, Inc. (ALZN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alzamend Neuro, Inc., an emerging growth company incorporated in Delaware, on September 25, 2025. The report covers events occurring between September 17, 2025, and September 25, 2025.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a specific equity transaction.
Material Changes
- Unregistered Sales of Equity Securities: Between September 17, 2025, and September 25, 2025, the Company issued 300,000 shares of Common Stock.
- Conversion Details: These shares were issued upon the conversion of 696 shares of Series B Convertible Preferred Stock.
- Regulatory Basis: The issuance relied on the exemption from registration requirements under Section 4(a)(2) of the Securities Act.
- Outstanding Shares: As of September 25, 2025, the total number of Common Stock shares outstanding was 3,439,861.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of the unregistered sale of securities.
Key Facts for Investor Verification
- Verify the impact of the 300,000 new shares on total outstanding equity (now 3,439,861 shares).
- Confirm the terms of the Series B Convertible Preferred Stock that was converted.
- Review the Company's cash position and burn rate in subsequent filings, as this 8-K does not disclose liquidity status.